CD19 and B-cell non-Hodgkin lymphoma: Building on our center’s experience with ASCT and sequential CAR-T therapy for refractory or relapsed aggressive B-cell non-Hodgkin lymphoma, we report for the first time the successful application of tandem CD19/20 CAR-T therapy combined with ASCT in the treatment of PCL.